Kestra Medical Technologies (KMTS)
Leases connected wearable defibrillator systems for patients at elevated sudden-cardiac-arrest risk.
Something off on this page? Send us feedback.
Leases the FDA-approved ASSURE WCD and connected recovery tools to U.S. patients at elevated sudden-cardiac-arrest risk, with revenue tied to prescriptions, patient adoption, and reimbursement from Medicare, Medicaid, private payors, healthcare organizations, and patients.
Built around the ASSURE Cardiac Recovery System, the business centers on ASSURE WCD, a wearable cardioverter defibrillator paired with monitoring and digital-health tools for adults at risk of sudden cardiac arrest who are not candidates for, or decline, an implantable defibrillator. The platform also includes the ASSURE patient app, Kestra CareStation, ASSURE Assist, and ASSURE Wearable ECG.
Revenue comes principally from month-to-month leases of ASSURE System devices to patients. Financial reporting uses a single operating and reportable segment, and filings say all leasing revenue for the periods presented was earned in the United States.
Execution depends on physician prescriptions, patient wear adoption, FDA-regulated indications, reimbursement from public and private payors, and direct WCD competition.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 21, 2026 | Oppenheimer | Initiate | Perform | ||
| Jul 15, 2026 | BTIG | Reiterate | Buy | $32 | |
| Jul 15, 2026 | Wolfe Research | Target | $30 | ||
| Jan 16, 2026 | Goldman Sachs | Target | $27 | $24 | |
| Jan 9, 2026 | Goldman Sachs | Target | $25 | $27 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Apr 30, 2026Cash & short-term investments $196.4M · Total debt $46.8M · Total assets $358.5M · Shareholders' equity $259.7M
- Revenue
- $28.6M
- Operating income
- −$39.3M
- Net income
- −$38.8M
No dividends on record.
| Institutions111 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 100.52% | 58.91M shares | |
| Insiders11 holders · as of Aug 18, 2026 | 1.71% | 1.00M shares | |
| Adds to | 102.23% |
58.60M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 102.23%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Bain Capital Investors LLCInstitution | 42.95% | 25.17M | 13Fas of Jun 30, 2026 |
Bain Charger Holdings, L.P.Institution | 42.95% | 25.17M | 13Gfiled Feb 17, 2026 ↗ |
FMR LLCInstitution | 9.43% | 5.52M | 13Fas of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 8.48% | 4.97M | 13Fas of Jun 30, 2026 |
Andera PartnersInstitution | 4.66% | 2.73M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Brian Daniel Webster | director, officer: See Remarks | −15,000 | $27.48 |
| Aug 7, 2026 | Vaseem Mahboob | officer: Chief Financial Officer | −26,287 | $25.88 |
| Aug 4, 2026 | Brian Daniel Webster | director, officer: See Remarks | −51,900 | $24.52 |
| Aug 4, 2026 | Traci S. Umberger | director, officer: See Remarks | −3,580 | $24.04 |
| Aug 4, 2026 | Vaseem Mahboob | officer: Chief Financial Officer | −6,995 | $24.68 |
- Medtronic
ICD, ICM, and CareLink platform rival in cardiac rhythm care
- Boston Scientific
S-ICD, insertable monitor, and LATITUDE remote-care rival
- Abbott
ICD, ICM, Merlin.net, and mobile remote-monitoring rival
- Philips (ADR)
MCOT and ePatch rival in connected ambulatory ECG monitoring
- iRhythm
Zio wearable ECG and AI reporting rival in ambulatory monitoring
- Stryker
Peripheral defibrillator rival through LIFEPAK emergency care
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kestra Medical Technologies | $25.75 | +2.51% | $1.51B | — | — | 15.9 | +66.2% |
| Medtronic | $92.40 | +0.22% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| Boston Scientific | $48.50 | +0.26% | $71.90B | 19.7 | 14.6 | 3.4 | +7.5% |
| Abbott | $111.49 | +0.93% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| Philips (ADR) | $26.27 | −0.44% | $25.77B | 19.6 | 13.5 | 1.3 | −2.9% |
| iRhythm | $121.95 | −0.55% | $4.03B | — | 245.7 | 4.9 | +20.1% |
| Stryker | $314.00 | +0.58% | $119.68B | 32.4 | 19.4 | 4.6 | +9.4% |
| Median | 22.7 | 17.2 | 3.8 | +11.2% |